These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15685833)

  • 1. Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
    Sun W; Whittington R; Gallagher M; O'Dwyer P; Giantonio B; Metz J; Haller D
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):39-42. PubMed ID: 15685833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
    Sun W; Metz JM; Gallagher M; O'Dwyer PJ; Giantonio B; Whittington R; Haller DG
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):621-7. PubMed ID: 20495918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan in esophageal cancer.
    Ilson DH; Minsky B
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):32-6. PubMed ID: 14569846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group.
    Leong T; Joon DL; Willis D; Jayamoham J; Spry N; Harvey J; Di Iulio J; Milner A; Mann GB; Michael M
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):690-5. PubMed ID: 20472363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
    Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan in the treatment of gastric cancer.
    Bugat R
    Ann Oncol; 2003; 14 Suppl 2():ii37-40. PubMed ID: 12810456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and irinotecan in upper gastrointestinal malignancies.
    O'Reilly EM; Ilson DH
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):42-5. PubMed ID: 11301840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
    Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M
    Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
    Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
    Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas.
    Karapetis CS; Cheong KA; Yip D; Strickland AH; Steer C; Marx G; Yip S; Chrystal K; Harper PG
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):298-305. PubMed ID: 21114780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
    Poorter RL; Bakker PJ; Fockens P; Taat CW; Bartelsman JF; Veenhof CH
    J Infus Chemother; 1996; 6(2):87-91. PubMed ID: 8809656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.
    Leong T; Michael M; Foo K; Thompson A; Lim Joon D; Weih L; Ngan S; Thomas R; Zalcberg J
    Br J Cancer; 2003 Oct; 89(8):1433-8. PubMed ID: 14562013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
    Ross P; Nicolson M; Cunningham D; Valle J; Seymour M; Harper P; Price T; Anderson H; Iveson T; Hickish T; Lofts F; Norman A
    J Clin Oncol; 2002 Apr; 20(8):1996-2004. PubMed ID: 11956258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
    Becerra CR
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):46-8. PubMed ID: 15685835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
    Kobayashi A; Yamaguchi M
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1755-9. PubMed ID: 9757202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
    Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
    J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation.
    Rischin D; Corry J; Smith J; Stewart J; Hughes P; Peters L
    J Clin Oncol; 2002 Apr; 20(7):1845-52. PubMed ID: 11919243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.